Ocaratuzumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | CD20 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H10016N1712O2010S44 |
| Molar mass | 145283.85 g·mol−1 |
Ocaratuzumab (AME-133v, LY2469298) is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders.[1] The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.[2]
Phase I/II trials in relapsed/refractory follicular lymphoma have been completed in the United States (US) and Japan, and a Phase I trial was conducted in US rheumatoid arthritis patients.[2] Phase III development in relapsed follicular lymphoma patients is underway.[3] Many patients relapse following currently available treatments, and a significant need for new effective treatment exists, particularly for patients with low-affinity FcγRIIIa allotypes.[4] In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as compared to rituximab.[2][4] Additional development in other oncology and rheumatology indications will also be pursued, as well as subcutaneous formations for patient convenience.[3]
This drug is currently being developed by Mentrik Biotech, LLC.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Ocaratuzumab" (PDF). American Medical Association.
- ^ a b c Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, et al. (March 2012). "Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma" (PDF). Clinical Cancer Research. 18 (5): 1395–403. doi:10.1158/1078-0432.CCR-11-0850. PMID 22223529.
- ^ a b "mentrik.com".
- ^ a b Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, et al. (February 2011). "Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma". Cancer Science. 102 (2): 432–8. doi:10.1111/j.1349-7006.2010.01809.x. PMID 21205069. S2CID 26346792.